Axsome Therapeutics (AXSM) Misses Q1 EPS by 43c

Axsome Therapeutics (NASDAQ: AXSM) reported Q1 EPS of ($1.26), $0.43 worse than the analyst estimate of ($0.83). Revenue for the quarter came in at $191.2 million versus the consensus estimate of $193.46 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Meta to invest $13 billion CAD in first Canadian data center
• Ardmore Shipping (ASC) 3400 contracts of July 17.50 calls trade, share price up 3.3%
• Broadcom (AVGO) spreader of 1467 contracts of July 31 weekly 410 and 435 calls